JP2024539089A5 - - Google Patents
Info
- Publication number
- JP2024539089A5 JP2024539089A5 JP2024523403A JP2024523403A JP2024539089A5 JP 2024539089 A5 JP2024539089 A5 JP 2024539089A5 JP 2024523403 A JP2024523403 A JP 2024523403A JP 2024523403 A JP2024523403 A JP 2024523403A JP 2024539089 A5 JP2024539089 A5 JP 2024539089A5
- Authority
- JP
- Japan
- Prior art keywords
- rrna
- modified
- molecule
- regulatory region
- replicase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021078828 | 2021-10-18 | ||
| EPPCT/EP2021/078828 | 2021-10-18 | ||
| PCT/EP2022/078869 WO2023066874A1 (en) | 2021-10-18 | 2022-10-17 | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539089A JP2024539089A (ja) | 2024-10-28 |
| JP2024539089A5 true JP2024539089A5 (https=) | 2025-10-22 |
Family
ID=78483247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523403A Pending JP2024539089A (ja) | 2021-10-18 | 2022-10-17 | 修飾複製可能ｒｎａの機能および関連する組成物を増加させるための変異を決定する方法ならびにそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250250626A1 (https=) |
| EP (1) | EP4419708A1 (https=) |
| JP (1) | JP2024539089A (https=) |
| CN (1) | CN118451194A (https=) |
| AU (1) | AU2022372325A1 (https=) |
| CA (1) | CA3234214A1 (https=) |
| WO (1) | WO2023066874A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119563028A (zh) * | 2022-05-12 | 2025-03-04 | 尚威天成信使核糖核酸治疗公司 | 具有分泌抗原和免疫调节物的合成自扩增mRNA分子 |
| IL326711A (en) | 2023-08-24 | 2026-04-01 | BioNTech SE | Systems and compositions comprising highly active trans-amplifying replicases |
| WO2025096982A1 (en) * | 2023-11-02 | 2025-05-08 | Amplitude Therapeutics, Inc. | Trans amplifying rnas comprising chemically modified nucleobases |
| WO2025129137A1 (en) * | 2023-12-14 | 2025-06-19 | Amplitude Therapeutics, Inc. | Two-component platform for trans amplifying rna (tarna) vaccination |
| WO2025157249A1 (zh) * | 2024-01-24 | 2025-07-31 | 南京金斯瑞生物科技有限公司 | 一种自复制rna及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008119827A1 (en) | 2007-04-02 | 2008-10-09 | Fit Biotech Oy | Transreplicase constructs |
| CN104072561B (zh) | 2007-06-19 | 2017-12-22 | 路易斯安那州州立大学及农业机械学院管理委员会 | 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途 |
| ES2840725T3 (es) | 2007-08-20 | 2021-07-07 | Glaxo Group Ltd | Procedimiento de producción |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| CA2766907A1 (en) * | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| LT4226941T (lt) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| MX2013002332A (es) | 2010-08-31 | 2013-03-18 | Novartis Ag | Lipidos apropiados para suministro liposomal del arn que codifica la proteina. |
| SI4043040T1 (sl) | 2010-08-31 | 2023-04-28 | Glaxosmithkline Biologicals Sa | Mali liposomi za dostavo imunogen-kodirajoče RNA |
| JP6059220B2 (ja) | 2011-07-06 | 2017-01-18 | ノバルティス アーゲー | 核酸を含む水中油型エマルジョン |
| EP4115875A1 (en) | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| MX350258B (es) | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
| MX366055B (es) | 2011-08-31 | 2019-06-26 | Novartis Ag | Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno. |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| EP3681904A1 (en) * | 2017-09-13 | 2020-07-22 | Biontech Cell&Gene Therapies GmbH | Rna replicon for expressing a t cell receptor or an artificial t cell receptor |
| WO2020146690A1 (en) * | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Methods for in vitro evolution of rna replicons |
| IL296752A (en) * | 2020-04-03 | 2022-11-01 | Gritstone Bio Inc | Infectious disease antigens and vaccines |
-
2022
- 2022-10-17 EP EP22802971.6A patent/EP4419708A1/en active Pending
- 2022-10-17 CN CN202280069737.1A patent/CN118451194A/zh active Pending
- 2022-10-17 AU AU2022372325A patent/AU2022372325A1/en active Pending
- 2022-10-17 CA CA3234214A patent/CA3234214A1/en active Pending
- 2022-10-17 US US18/702,287 patent/US20250250626A1/en active Pending
- 2022-10-17 JP JP2024523403A patent/JP2024539089A/ja active Pending
- 2022-10-17 WO PCT/EP2022/078869 patent/WO2023066874A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024539089A5 (https=) | ||
| Morais et al. | The critical contribution of pseudouridine to mRNA COVID-19 vaccines | |
| JP6929791B2 (ja) | エピゲノム編集のための組成物および方法 | |
| RU2652899C1 (ru) | РНК-проводники для подавления репликации вируса гепатита B и для элиминации вируса гепатита B из клетки-хозяина | |
| Tusup et al. | Design of in vitro transcribed mRNA vectors for research and therapy | |
| JP2021137036A5 (https=) | ||
| US20050112752A1 (en) | Method for the purification of alphavirus replicon particles | |
| JP2023509964A5 (https=) | ||
| Wang et al. | Recoding of the vesicular stomatitis virus L gene by computer-aided design provides a live, attenuated vaccine candidate | |
| JP2020510426A5 (https=) | ||
| Le Nouën et al. | Attenuation of human respiratory viruses by synonymous genome recoding | |
| CN118147171B (zh) | 具有增强的外源基因表达水平的自扩增mRNA核酸序列 | |
| CN118222588B (zh) | 一种减毒型弓形虫疫苗株及其制备方法和在抗肿瘤中的应用 | |
| WO2023035372A1 (zh) | 一种有限自我复制mRNA分子系统、制备方法及应用 | |
| US20230079750A1 (en) | Calr and jak2 t-cell receptors | |
| JP2022513718A5 (https=) | ||
| Pereira-Gómez et al. | Altering compositional properties of viral genomes to design live-attenuated vaccines | |
| Xu et al. | From sequence to system: Enhancing IVT mRNA vaccine effectiveness through cutting-edge technologies | |
| JP2024546964A5 (https=) | ||
| CN106754922A (zh) | 调控自身增殖的轮状病毒编码的小rna分子 | |
| JP2024542126A5 (https=) | ||
| CN120888569A (zh) | 一种自复制mRNA疫苗及其制备方法和用途 | |
| JP2024529108A5 (https=) | ||
| CN119639774A (zh) | 自复制rna分子组合及其应用 | |
| CN120379688A (zh) | 一种自复制rna及其用途 |